| Literature DB >> 860047 |
J F Sackett, C M Strother, C E Quaglieri, M J Javid, A B Levin, T A Duff.
Abstract
Two-hundred-fifteen patients were evaluated with metrizamide, a new water-soluble contrast agent for use in the subarachnoid spaces. Side effects were reported in 67% of these; 39% were moderate or severe. Cervical injections monitored by fluoroscopy provide the most precise positioning of the medium. The benefits of metrizamide use outweigh its risk.Entities:
Mesh：
Substances：
Year: 1977 PMID： 860047 DOI： 10.1148/123.3.779
Source DB: PubMed Journal: Radiology ISSN： 0033-8419 Impact factor: 11.105